sar442970
mAbexperimentalBi-specific
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2023 (NCT05849922)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
TNFSF4 inhibitor
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068097 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170917 | Phase 2 | Nov 6, 2025 | Sanofi |
| NCT06975722 | Phase 2 | Jul 7, 2025 | Sanofi |
| NCT06958536 | Phase 2 | Jun 3, 2025 | Sanofi |
| NCT06812988 | Phase 2 | Feb 12, 2025 | Sanofi |
| NCT06500702 | Phase 2 | Aug 22, 2024 | Sanofi |
| NCT05849922 | Phase 2 | Jun 6, 2023 | Sanofi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 6 | 6 | 1 | 2023 |
1 organizations
Page 1 / 1